Site for DV0004 A MULTICENTER RANDOMIZED OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF THE PREFILLED SAFETY SYRINGE OR AUTO-INJECTOR FOR THE SUBCUTANEOUS SELF-INJECTION OF BIMEKIZUMAB SOLUTION BY SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
Site for DV0004 is a Phase 3, multicenter, open-label, randomized, noncomparator, North America and Europe substudy to PA0012 in adult subjects with active psoriatic arthritis (PsA) to evaluate the safe and effective use of 2 single-use disposable self-injecting device presentations for the subcutaneous (sc) administration of bimekizumab solution (the investigational medicinal product [IMP]). To provide patients with PsA with options for the self-administration of bimekizumab, DV0004 will evaluate 2 investigational self-injecting device presentations, which are drugproduct (IMP) associated with a functional secondary packaging: the 1mL bimekizumab safety syringe (bimekizumab-SS-1mL) and the 1mL bimekizumab auto-injector(bimekizumab-AI-1mL).
Site for I4V-MC-JAJD - A Randomized Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Site for Study I4V-MC-JAJD (JAJD) is a Phase 3b/4, multicenter, randomized, parallel-group,active-controlled, pragmatic, event-driven study to evaluate the effects of baricitinib (2 mg and 4 mg daily) compared with tumor necrosis factor (TNF) inhibitors (administered according to approved local labeling) on risk of VTE and other key safety endpoints in patients with RA receiving routine clinical care. Consistent with the pragmatic intent of this study, once randomized, treatment will be provided through mechanisms available to patients in routine care and will be open-label for patients and study-site personnel.
Site for Intermediate Patient Population Expanded Access Protocol for MBP134 for Participants with Sudan Virus Disease (SVD)
The goal of this study is to see if a drug called MBP134 works to help patients get better from Sudan Virus Disease (SVD).
Site for Mechanistic registry to examine whether the corona virus disease 2019 (COVID-19) accelerates atherosclerotic plaque progression
The purpose of this study is to determine if coronary disease patientswith a history of COVID-19 infection have more inflammation, resultingin faster development of plaque in their coronary arteries whencompared to patients with no prior history of COVID-19 infection.
Site for Registry of Asthma Patients Initiating
Site for Participant in this observational research study sponsored by Regeneron Pharmaceuticals, Inc., are being asked to participate because they are receiving treatment with dupilumab, since you are currently being treated for asthma by a study participating physician. The study is being done to characterize and collect long term data on patients 12 years and older with moderate to severe asthma, who receive treatment with dupilumab (also known as DUPIXENT®).
Site for Studies of Patients with Implanted Intracranial Electrodes
Site for The overall goals of this research protocol are 1) to better understand the function of cortical sites that are measured with scalp electrodes (electroencephalography, or EEG) and/or implanted intracranial electrodes (electrocorticography, or ECoG) and 2) to determine the most effective and safe testing methods, including cortical stimulation and passive EEG or ECoG recordings, for defining this cortical function so that post-operative neurological impairments are avoided.
Site for Understanding health disparities in Pakistani Bangladeshi and Asian Indian immigrants: the role of socio-cultural context acculturation and resilience resources - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study Expansion New York Site
Site for This protocol describes a mixed methods study that leverages the infrastructure of an ongoing MASALA study in Chicago and San Francisco to enroll 600 Bangladeshi and 250 Pakistani adults aged 40-84 years as part of a greater New York City cohort. These participants will be added to the 1,550 surviving participants already in MASALA for well-powered subgroup comparisons and ongoing follow-up. Participants will complete a physical exam and survey, provide biospecimens, and be followed longitudinally (12M, 24M) to complete surveys in order to identify how socio-cultural context, discrimination, acculturation strategies and resilience resources act as risk or protective factors explaining CVH disparities in Indian, Pakistani and Bangladeshi immigrants.
Site for WUH APOLLO TRIAL: Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial
Site for Multi-center, global, prospective, randomized, interventional, pre-market trial Subjects will be randomized on 1:1 basis to either TMVR with the Medtronic Intrepid™ TMVRSystem or to conventional mitral valve surgery.Subjects ineligible for randomization may be enrolled through a single-arm trial. Subjectsenrolled in the single-arm cohort will be assigned to TMVR with the Medtronic Intrepid™ TMVR System
Site for WUH TrialNet: NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES
Site for The TrialNet Natural History Study of the Development of T1D is divided into Screening and Monitoring stages. Each stage will require separate informed consent for entry. Screening involves testing relatives of individuals with diabetes for the presence of islet autoantibodies. Individuals who have autoantibodies will be enrolled into the Monitoring stage (see Appendix Schedule of Assessments). The study will use a prospective cohort design.The algorithm below shows the flow of participants in the Screening and Monitoring stages. The Screening stage involves measurement of GAD65A, IA-2A, and mIAA, (with a positive result for any of these leading to measurement of ICA and ZnT8A) to determine whether the participant is eligible for the Monitoring stage. As additional diabetes-related autoantibodies are discovered and validated, they may also be included in Screening. Participants will be eligible for Monitoring if they have at least two positive autoantibodies on a Screening sample or at least one positive autoantibody on two separate Screening samples. Participants younger than 18 years old who are negative for all autoantibodies will be offered annual autoantibody rescreening until their 18th birthday. Participants 18 or older with a single positive autoantibody on the first Screening sample but no positive autoantibodies on a confirmatory test will be offered annual rescreening for two years.
Sjogren's Syndrome | NYU Langone Health
NYU Langone rheumatologists diagnose and treat Sjogren’s syndrome, an autoimmune disorder.